Defects in protein citrullination and its consequences in patients with RA have been studied widely in the recent decade. It appears that autoantibodies, including those against citrullinated proteins, are of diagnostic and prognostic relevance.
One million people are hospitalized each year with sepsis. This is more than the number of hospitalizations for heart attack and stroke combined. Sepsis can be a particular risk for older people.
Researchers have determined that adults aged 50 and above were more likely to acquire pain relievers through more than one doctor, whereas younger individuals were more likely to acquire them from friends, relatives or drug dealers.
FDA announced yesterday they would strengthen warnings stating that non-aspirin nonsteroidal anti-inflammatory drugs increase the chance of a heart attack or stroke. This applies to both prescription and OTC NSAIDs.
A slim, yoga bending, middle aged school teacher seeks a rheumatology consultation to determine the cause and cure for her left lateral heel pain for the past 6 months. No trauma, no crazy footwear and no systemic symptoms, uveitis, or peripheral/axial arthritis.
Yesterday Health Canada announced it “is taking additional steps to minimize the risk of liver damage and improve acetaminophen safety,” citing the findings of a government review that underscored the possibility of accidental overdose.
The anti-citrullinated peptide (anti-CCP or ACPA) antibody assay has a specificity of greater than 90% for rheumatoid arthritis and is associated with worse articular outcomes.
NEJM reports a 52 week, phase II trial in 293 adult patients with moderate-to-severe psoriasis (>10 BSA) who were randomized to receive either placebo, adalimumab or guselkumab - a novel IL-23 inhibitor.
Colchicine toxicity has been linked to renal function and it has generally been advised to adjust colchicine dosing in patients with renal insufficiency.
On May 26, RheumNow.com reported that Amgen and Astra-Zenica suspended drug development for the IL-17 inhibitor brodalumab.
Demyelinating disorders are an uncommon complication of TNF inhibition and have been described with all TNF inhibitors but also with other biologics.
With three months until the switch from ICD-9 to ICD-10 coding, CMS and the AMA have announced efforts to continue to help physicians get ready ahead of the October 1 deadline.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
